Lyra Therapeutics (LYRA) Competitors $0.14 -0.01 (-8.32%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$0.14 0.00 (-0.71%) As of 03/28/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LYRA vs. SPAI, DXR, BDMD, FEMY, CLGN, POCI, NXL, NMTC, PYPD, and DRIOShould you be buying Lyra Therapeutics stock or one of its competitors? The main competitors of Lyra Therapeutics include Safe Pro Group Inc. Common Stock (SPAI), Daxor (DXR), Baird Medical Investment (BDMD), Femasys (FEMY), CollPlant Biotechnologies (CLGN), Precision Optics (POCI), Nexalin Technology (NXL), NeuroOne Medical Technologies (NMTC), PolyPid (PYPD), and DarioHealth (DRIO). These companies are all part of the "medical equipment" industry. Lyra Therapeutics vs. Safe Pro Group Inc. Common Stock Daxor Baird Medical Investment Femasys CollPlant Biotechnologies Precision Optics Nexalin Technology NeuroOne Medical Technologies PolyPid DarioHealth Safe Pro Group Inc. Common Stock (NASDAQ:SPAI) and Lyra Therapeutics (NASDAQ:LYRA) are both small-cap business services companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, community ranking, analyst recommendations, institutional ownership, media sentiment, risk and valuation. Does the MarketBeat Community believe in SPAI or LYRA? Lyra Therapeutics received 24 more outperform votes than Safe Pro Group Inc. Common Stock when rated by MarketBeat users. CompanyUnderperformOutperformSafe Pro Group Inc. Common StockN/AN/ALyra TherapeuticsOutperform Votes2458.54% Underperform Votes1741.46% Does the media prefer SPAI or LYRA? In the previous week, Lyra Therapeutics had 1 more articles in the media than Safe Pro Group Inc. Common Stock. MarketBeat recorded 2 mentions for Lyra Therapeutics and 1 mentions for Safe Pro Group Inc. Common Stock. Safe Pro Group Inc. Common Stock's average media sentiment score of 1.90 beat Lyra Therapeutics' score of 0.43 indicating that Safe Pro Group Inc. Common Stock is being referred to more favorably in the media. Company Overall Sentiment Safe Pro Group Inc. Common Stock Very Positive Lyra Therapeutics Neutral Do analysts recommend SPAI or LYRA? Lyra Therapeutics has a consensus price target of $1.25, suggesting a potential upside of 792.86%. Given Lyra Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Lyra Therapeutics is more favorable than Safe Pro Group Inc. Common Stock.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Safe Pro Group Inc. Common Stock 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Lyra Therapeutics 1 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has higher valuation & earnings, SPAI or LYRA? Safe Pro Group Inc. Common Stock has higher revenue and earnings than Lyra Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSafe Pro Group Inc. Common Stock$1.56M23.39N/AN/AN/ALyra Therapeutics$1.53M6.01-$62.68M-$1.43-0.10 Do institutionals & insiders hold more shares of SPAI or LYRA? 95.6% of Lyra Therapeutics shares are owned by institutional investors. 4.7% of Lyra Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is SPAI or LYRA more profitable? Safe Pro Group Inc. Common Stock has a net margin of 0.00% compared to Lyra Therapeutics' net margin of -6,635.76%. Safe Pro Group Inc. Common Stock's return on equity of 0.00% beat Lyra Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Safe Pro Group Inc. Common StockN/A N/A N/A Lyra Therapeutics -6,635.76%-125.07%-59.74% SummaryLyra Therapeutics beats Safe Pro Group Inc. Common Stock on 7 of the 13 factors compared between the two stocks. Remove Ads Get Lyra Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LYRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LYRA vs. The Competition Export to ExcelMetricLyra TherapeuticsSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.15M$4.35B$5.63B$7.84BDividend YieldN/A48.03%5.33%4.01%P/E Ratio-0.0928.4223.5818.74Price / Sales6.0149.24388.2390.77Price / CashN/A51.0838.1734.64Price / Book0.096.116.894.23Net Income-$62.68M$67.64M$3.20B$247.47M7 Day Performance-20.00%-5.25%-3.06%-2.29%1 Month Performance-34.58%-4.12%1.51%-5.81%1 Year Performance-97.75%10.65%9.37%-0.96% Lyra Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LYRALyra Therapeutics2.6528 of 5 stars$0.14-8.3%$1.25+792.9%-97.7%$9.15M$1.53M-0.0950Short Interest ↑SPAISafe Pro Group Inc. Common StockN/A$2.94+0.7%N/AN/A$40.45M$1.56M0.0011DXRDaxor4.0778 of 5 stars$8.15-2.2%$25.00+206.7%-9.8%$39.42M$2.13M0.0037BDMDBaird Medical InvestmentN/A$5.67-1.6%N/AN/A$37.33M$33.05M0.00N/AFEMYFemasys2.278 of 5 stars$1.56-2.5%$11.50+637.2%-16.8%$35.72M$1.26M-1.9330Earnings ReportAnalyst ForecastShort Interest ↑News CoverageCLGNCollPlant Biotechnologies2.8234 of 5 stars$3.11+0.3%$12.50+301.9%-52.3%$35.63M$650,000.00-2.0270Earnings ReportAnalyst ForecastShort Interest ↓News CoverageHigh Trading VolumePOCIPrecision Optics0.3176 of 5 stars$4.41-6.7%N/A-25.6%$33.69M$18.68M-6.8980Short Interest ↑News CoverageNXLNexalin Technology3.249 of 5 stars$2.34-1.7%$5.00+113.7%+36.4%$31.13M$168,721.00-3.663Short Interest ↓Positive NewsGap UpNMTCNeuroOne Medical Technologies0.8159 of 5 stars$0.97-5.8%N/A-28.3%$29.94M$5.75M-3.7320Short Interest ↓Positive NewsPYPDPolyPid2.7351 of 5 stars$2.94+4.4%$11.33+286.1%-40.4%$29.91MN/A-0.5980Short Interest ↓Gap DownDRIODarioHealth2.6347 of 5 stars$0.70+1.7%$1.50+114.3%-59.3%$29.10M$27.04M-0.74200 Remove Ads Related Companies and Tools Related Companies SPAI Competitors DXR Competitors BDMD Competitors FEMY Competitors CLGN Competitors POCI Competitors NXL Competitors NMTC Competitors PYPD Competitors DRIO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LYRA) was last updated on 3/30/2025 by MarketBeat.com Staff From Our PartnersTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredAI Boom Takes a Shocking Turn…A potentially historic moment for retirement Let's make the most of this market together. Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredHuge Elon-backed AI rollout begins – buy these nine stocksIf you suspect Elon Musk has an ulterior motive for coming to Washington, D.C.... You're 100% correct. ...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lyra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lyra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
